Two Sigma Investments
DSGN icon

Two Sigma Investments’s Design Therapeutics DSGN Stock Holding History

Two Sigma Investments’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173K Sell
16,300
-29,937
-65% -$303K ﹤0.01% 4305
2025
Q4 		$434K Sell
46,237
-13,000
-22% -$102K ﹤0.01% 3390
2025
Q3 		$446K Sell
59,237
-30,074
-34% -$151K ﹤0.01% 3032
2025
Q2 		$301K Sell
89,311
-39,436
-31% -$148K ﹤0.01% 2787
2025
Q1 		$497K Sell
128,747
-75,184
-37% -$359K ﹤0.01% 2525
2024
Q4 		$1.26M Sell
203,931
-100,313
-33% -$581K ﹤0.01% 2026
2024
Q3 		$1.64M Sell
304,244
-98,471
-24% -$463K ﹤0.01% 1798
2024
Q2 		$1.35M Sell
402,715
-19,320
-5% -$75.3K ﹤0.01% 1805
2024
Q1 		$1.7M Sell
422,035
-6,136
-1% -$16.4K ﹤0.01% 1600
2023
Q4 		$1.13M Buy
428,171
+364,336
+571% +$835K ﹤0.01% 2003
2023
Q3 		$151K Sell
63,835
-51,947
-45% -$242K ﹤0.01% 2694
2023
Q2 		$729K Sell
115,782
-63,314
-35% -$387K ﹤0.01% 2135
2023
Q1 		$1.03M Buy
179,096
+144,003
+410% +$1.08M ﹤0.01% 1850
2022
Q4 		$360K Buy
+35,093
New +$476K ﹤0.01% 2169

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments's DSGN Position: Q1 2026 in Review

Two Sigma Investments reduced its Design Therapeutics (DSGN) stake by 65% in Q1 2026, selling an estimated $303K and leaving 16,300 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #4305.

Two Sigma Investments first reported a position in DSGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.7M in Q1 2024. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Two Sigma Investments held 16,300 shares of Design Therapeutics worth $173K as of Q1 2026.
  • Two Sigma Investments sold 29,937 Design Therapeutics shares in Q1 2026, an estimated $303K.
  • Design Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4305 holding.
  • Two Sigma Investments first reported a position in Design Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Two Sigma Investments's Design Therapeutics position peaked at $1.7M in Q1 2024.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.